natgillin/translations-raw huggingface dataset:
As this product is given by a doctor or other healthcare professional, it is very unlikely that you will be given too much Zerbaxa. 
Če ste prejeli večji odmerek zdravila Zerbaxa, kot bi smeli Zdravilo Zerbaxa vam bo dal zdravnik ali drug zdravstveni delavec, zato je zelo malo verjetno, da bi ga prejeli preveč.
The following adverse reactions have been identified during clinical trials with Zerbaxa. 
V kliničnih preskušanjih zdravila Zerbaxa so ugotovili naslednje neželene učinke.
See section 4.2 for recommended dose regimens for Zerbaxa based on indication and renal function. 
Za priporočene sheme odmerjanja zdravila Zerbaxa glede na indikacijo in delovanje ledvic glejte poglavje 4.2.
2 g ceftolozane / 1 g tazobactam 
2 g ceftolozana/ 1 g tazobaktama na 8 ur
Infections caused by bacteria that are not sensitive to Zerbaxa or caused by a fungus can occur during or following treatment with Zerbaxa. 
Med zdravljenjem ali po zdravljenju z zdravilom Zerbaxa se lahko pojavijo okužbe, ki jih povzročijo bakterije, ki niso občutljive na zdravilo Zerbaxa, ali okužbe, ki jih povzročijo glive.
Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion 
Zerbaxa 1 g/0,5 g prašek za koncentrat za raztopino za infundiranje
The elimination half-life (t½) of ceftolozane or tazobactam is independent of dose. 
Eliminacijski razpolovni čas (t1/2) ceftolozana ali tazobaktama ni odvisen od odmerka.
In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in ceftolozane/tazobactam AUC were observed in Caucasians compared to other ethnicities. 
Populacijska farmakokinetična analiza ceftolozana/tazobaktama ni pokazala klinično pomembnih razlik AUC ceftolozana/tazobaktama pri belcih v primerjavi z drugimi etničnimi skupinami.
The ceftolozane dose normalized geometric mean AUC increased up to 1.26-fold, 2.5-fold, and 5-fold in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects with normal renal function. 
V primerjavi z zdravimi osebami z normalnim delovanjem ledvic se je geometrična sredina AUC ceftolozana, normalizirana na odmerek, pri osebah z blago okvaro ledvic povečala za 1,26-krat, z zmerno okvaro ledvic za 2,5-krat in s hudo okvaro ledvic za 5-krat.
What Zerbaxa looks like and contents of the pack Zerbaxa is a white to slightly yellow powder for concentrate for solution for infusion (powder for concentrate) supplied in a vial. 
Zdravilo Zerbaxa je bel do rumenkast prašek za koncentrat za raztopino za infundiranje (prašek za koncentrat) v viali.
See section 6.6 for instructions on reconstitution and dilution of the medicinal product before administration. 
Za navodila glede priprave in redčenja zdravila pred dajanjem glejte poglavje 6.6.
These may be signs of a severe allergic reaction (anaphylaxis) and may be lifethreatening - Diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with Zerbaxa. 
- driska, ki postane huda ali ki ne mine, ali kri ali sluz v blatu med ali po zdravljenju z zdravilom Zerbaxa.
Complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis** 
Zapletene okužbe v trebušni votlini, zapletene okužbe sečil in akutni pielonefritis**
A single loading dose of 500 mg ceftolozane / 250 mg tazobactam followed after 8 hours by a 100 mg ceftolozane / 50 mg tazobactam maintenance dose administered every 8 hours for the remainder of the treatment period (on haemodialysis days, the dose should be administered at the earliest possible time following completion of haemodialysis) 
500 mg ceftolozana/250 mg tazobaktama intravensko na 8 ur končna odpoved ledvic na hemodializi enkratni polnilni odmerek 500 mg ceftolozana/250 mg tazobaktama, ki mu po 8 urah sledi vzdrževalni odmerek 100 mg ceftolozana/50 mg tazobaktama vsakih 8 ur do zaključka zdravljenja (ob dneh hemodialize je treba odmerek uporabiti čim prej po koncu hemodialize)
Infections and infestations Clostridioides difficile colitis 
1, okužbe s Clostridioides difficile
2, blood alkaline phosphatase increased 2, gammaglutamyltransferase increased 
2, zvišana alkalna fosfataza v krvi
Tabulated list of adverse reactions for complicated intra-abdominal infections, complicated urinary tract infections, including pyelonephritis, and hospital-acquired pneumonia, including ventilator-associated pneumonia 
Seznam neželenih učinkov pri zapletenih okužbah v trebušni votlini, zapletenih okužbah sečil, vključno s pielonefritisom, in bolnišnični pljučnici, vključno s pljučnico, povezano z umetnim predihavanjem
1, dizziness 
1, anksioznost
- Each vial contains ceftolozane sulfate equivalent to 1 g ceftolozane and tazobactam sodium equivalent to 0.5 g tazobactam. 
- Ena viala vsebuje ceftolozan sulfat, kolikor ga ustreza 1 g ceftolozana, in natrijev tazobaktamat,
The incidence of seroconversion to a positive direct Coombs test was 0.2% in patients receiving Zerbaxa and 0% in patients receiving the comparator in the complicated intra-abdominal infections and complicated urinary tract infections clinical trials. 
V kliničnih preskušanjih pri zapletenih okužbah v trebušni votlini in zapletenih okužbah sečil je bila pojavnost serokonverzije v pozitiven izvid direktnega Coombsovega testa 0,2 % pri bolnikih, ki so prejemali zdravilo Zerbaxa, in 0 % pri bolnikih, ki so prejemali primerjalno zdravilo.
Talk to your doctor or pharmacist before taking Zerbaxa if you know you are, or have previously been allergic to cephalosporins, penicillins or other antibiotics. 
Če veste, da ste alergični, ali ste v preteklosti bili alergični na cefalosporine, peniciline ali druge antibiotike, se pred začetkom uporabe zdravila Zerbaxa posvetujte z zdravnikom ali farmacevtom.
1 g ceftolozane / 0.5 g tazobactam intravenously every 8 hours 
1 g ceftolozana/0,5 g tazobaktama intravensko na 8 ur
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja izpuščaj urtikarija
Zerbaxa 1 g / 0.5 g powder for concentrate ceftolozane / tazobactam 
Zerbaxa 1 g / 0,5 g prašek za koncentrat ceftolozan / tazobaktam
Complicated intra-abdominal infection* 
Zapletene okužbe v trebušni votlini*
1 g ceftolozane / 0.5 g tazobactam 
1 g ceftolozana/ 0,5 g tazobaktama na 8 ur
Specific for the complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections indications treated with Zerbaxa (1 g / 0.5 g intravenously every 8 hours) for up to 14 days. 
1, pozitiven test za Clostridioides Značilno za indikacije zapletene okužbe v trebušni votlini, akutni pielonefritis in zapletene okužbe sečil, zdravljene z zdravilom Zerbaxa (1 g/0,5 g intravensko na 8 ur) do 14 dni.
Hospital-acquired pneumonia, including ventilator-associated pneumonia** 
Bolnišnična pljučnica, vključno s pljučnico, povezano z umetnim predihavanjem**
Hospital-acquired pneumonia, including ventilator-associated pneumonia 
Bolnišnična pljučnica, vključno s pljučnico, povezano z umetnim predihavanjem
In clinical studies, there was no evidence of haemolysis in patients who developed a positive DAGT on treatment. 
Pri bolnikih, pri katerih je v kliničnih študijah med zdravljenjem prišlo do pozitivnega DAGT, ni bilo dokazov o hemolizi.
How to store Zerbaxa 
Shranjevanje zdravila Zerbaxa
Hepatic impairment 
Psihiatrične motnje nespečnost
1, anxiety Nervous system disorders Headache 
Bolezni živčevja glavobol
Gram-negative bacteria Escherichia coli Klebsiella pneumoniae Proteus mirabilis 
Gramnegativne bakterije Escherichia coli Klebsiella pneumoniae
Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam 
Zerbaxa 1 g / 0,5 g prašek za koncentrat za raztopino za infundiranje ceftolozan / tazobaktam
A decline in renal function has been seen in patients receiving ceftolozane/tazobactam. 
Pri bolnikih, ki so prejemali ceftolozan/tazobaktam, so opazili zmanjšano delovanje ledvic.
1, renal failure 
1, odpoved ledvic
Antibacterial-associated colitis and pseudomembranous colitis have been reported with ceftolozane/tazobactam (see section 4.8). 
Pri uporabi ceftolozana/tazobaktama so poročali o kolitisu in psevdomembranskem kolitisu, povezanima z antibiotikom (glejte poglavje 4.8).
Complicated intra-abdominal infections* Complicated urinary tract infections* Acute pyelonephritis* 
Enterobacterales zapletene okužbe v trebušni votlini* zapletene okužbe sečil* akutni pielonefritis*
Complicated intra-abdominal infections* Complicated urinary tract infections* Acute pyelonephritis* Hospital-acquired pneumonia, including ventilator-associated pneumonia** 
P. aeruginosa zapletene okužbe v trebušni votlini* zapletene okužbe sečil* akutni pielonefritis* bolnišnična pljučnica, vključno s pljučnico, povezano z umetnim predihavanjem**
Hyperglycaemia hypomagnesaemia hypophosphataemia 
Presnovne in prehranske motnje hipokaliemija hiperglikemija hipomagneziemija hipofosfatemija
For preparation of the 1.5 g ceftolozane / 0.75 g tazobactam dose: Withdraw the entire contents from one reconstituted vial (approximately 11.4 mL per vial) and 5.7 mL from a second reconstituted vial using a syringe and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 1,5 mg ceftolozana/0,75 g tazobaktama: Z brizgo izvlecite celotno vsebino ene rekonstituirane viale (približno 11,4 ml na vialo) in 5,7 ml iz druge rekonstituirane viale in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
Tazobactam is a beta-lactam structurally related to penicillins. 
Tazobaktam je betalaktam, po zgradbi soroden penicilinom.
Candidiasis including oropharyngeal and vulvovaginal Clostridioides difficile colitis fungal urinary tract infection Clostridioides difficile infection 
Infekcijske in parazitske bolezni kolitis zaradi Clostridioides difficile kandidoza, vključno z orofaringealno in vulvovaginalno
No dose adjustment is recommended for ceftolozane/tazobactam in subjects with hepatic impairment (see section 4.2). 
Pri bolnikih z okvaro jeter prilagoditev odmerka ceftolozana/tazobaktama ni potrebna (glejte poglavje 4.2).
Dyspnoea 
Odmerek
For preparation of the 2 g ceftolozane / 1 g tazobactam dose: Withdraw the entire contents from two reconstituted vials (approximately 11.4 mL per vial) using a syringe and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 2 g ceftolozana/1 g tazobaktama: Z brizgo izvlecite celotno vsebino iz dveh rekonstituiranih vial (približno 11,4 ml na vialo) in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
Zerbaxa was evaluated in Phase 3 comparator-controlled clinical trials of complicated intra-abdominal infections and complicated urinary tract infections (including pyelonephritis), which included a total of 1,015 patients, treated with Zerbaxa (1 g / 0.5 g intravenously every 8 hours, adjusted to match renal function where appropriate) for up to 14 days. 
V preskušanja je bilo vključenih skupaj 1.015 bolnikov, ki so se do 14 dni zdravili z zdravilom Zerbaxa (1 g/0,5 g intravensko na 8 ur, prilagojeno delovanju ledvic, če je bilo potrebno).
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1; - Hypersensitivity to any cephalosporin antibacterial agent; - Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or carbapenems). 
- Huda preobčutljivost (npr. anafilaktična reakcija, huda kožna reakcija) na katero koli drugo vrsto betalaktamskih antibiotikov (npr. na peniciline ali karbapeneme).
In addition tazobactam does not inhibit the following types of beta-lactamase: 
Tazobaktam ne zavira vseh encimov skupine A. Prav tako tazobaktam ne zavira naslednjih tipov betalaktamaz:
For preparation of the 1 g ceftolozane / 0.5 g tazobactam dose: Withdraw the entire contents (approximately 11.4 mL) of the reconstituted vial using a syringe and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 1 g ceftolozana/0,5 g tazobaktama: Z brizgo izvlecite celotno vsebino rekonstituirane viale (približno 11,4 ml) in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
For preparation of the 250 mg ceftolozane / 125 mg tazobactam dose: Withdraw 2.9 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 250 mg ceftolozana/125 mg tazobaktama: 2,9 ml vsebine izvlecite iz rekonstituirane viale in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
For preparation of the 300 mg ceftolozane / 150 mg tazobactam dose: Withdraw 3.5 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 300 mg ceftolozana/150 mg tazobaktama: 3,5 ml vsebine izvlecite iz rekonstituirane viale in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
Zerbaxa was evaluated in a Phase 3 comparator-controlled clinical trial of hospital-acquired pneumonia, including ventilator-associated pneumonia, which included a total of 361 patients, treated with Zerbaxa (2 g / 1 g intravenously every 8 hours, adjusted to match renal function where appropriate) for up to 14 days. 
Preskušanje je zajelo 361 bolnikov, ki so do 14 dni prejemali zdravilo Zerbaxa (2 g/1 g intravensko na 8 ur, prilagojeno delovanju ledvic, če je bilo treba).
Peri/postnatal development was impaired (reduced pup weights, increase in stillbirths, increase in pup mortality) concurrent with maternal toxicity after intraperitoneal administration of tazobactam in the rat. 
Po intraperitonealni uporabi tazobaktama pri podganah so poleg toksičnih učinkov pri samicah - materah opažali prizadetost peri- in postnatalnega razvoja (manjša telesna masa mladičev, več mrtvoskotenosti, večja umrljivost mladičev).
For preparation of the 500 mg ceftolozane / 250 mg tazobactam dose: Withdraw 5.7 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 500 mg ceftolozana/250 mg tazobaktama: 5,7 ml vsebine izvlecite iz rekonstituirane viale in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
Complicated urinary tract infections 
Zapletene okužbe sečil Akutni pielonefritis
For preparation of the 100 mg ceftolozane / 50 mg tazobactam dose: Withdraw 1.2 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 
Za pripravo odmerka 100 mg ceftolozana/50 mg tazobaktama: 1,2 ml vsebine izvlecite iz rekonstituirane viale in jo dodajte v infuzijsko vrečko, ki vsebuje 100 ml 0,9 % natrijevega klorida za injiciranje (fiziološke raztopine) ali 5 % glukoze za injiciranje.
Nausea 
Občutljivi
Complicated intra-abdominal infections 
Zapletene okužbe sečil
Sodium chloride Arginine 
6.1 Seznam pomožnih snovi natrijev klorid arginin citronska kislina, brezvodna
No dose adjustment of ceftolozane/tazobactam is recommended for hospital-acquired pneumonia, including ventilatorassociated pneumonia patients with augmented renal clearance. 
Pri bolnikih z bolnišnično pljučnico, vključno s pljučnico, povezano z umetnim predihavanjem, ki imajo povečan očistek kreatinina odmerka ceftolozana/tazobaktama ni treba prilagoditi.
This summary was last updated in 07-2014. 
Povzetek je bil nazadnje posodobljen 07-2014.
The full EPAR for Ratiograstim can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ratiograstim je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Ratiograstim on 15 September 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Ratiograstim, veljavno po vsej Evropski uniji, izdala 15. septembra 2008.
This means that Ratiograstim is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine'). 
To pomeni, da je podobno biološkemu zdravilu, ki je že odobreno v Evropski uniji (EU) in vsebujejo enako zdravilno učinkovino (t.i. „referenčno zdravilo“).
During the first 21-day chemotherapy cycle, patients treated with either Ratiograstim or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo. 
Med prvim 21-dnevnim ciklom kemoterapije so imeli bolniki, zdravljeni bodisi z zdravilom Ratiograstim ali Neupogen, hudo nevtropenijo v povprečju 1,1 dan, v primerjavi s 3,8 dneva pri tistih, ki so prejemali placebo.
This is a summary of the European public assessment report (EPAR) for Ratiograstim. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ratiograstim.
What measures are being taken to ensure the safe and effective use of Ratiograstim? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ratiograstim?
How it is given, the dose and the duration of treatment depend on why it is being used, the patient's body weight and the response to treatment. 
Način dajanja zdravila, odmerek in trajanje zdravljenja so odvisni od vzroka za uporabo zdravila, bolnikove telesne mase in odziva na zdravljenje.
Filgrastim is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced, which makes them able to produce filgrastim. 
Filgrastim se izdeluje z metodo, imenovano „tehnologija rekombinantne DNK“: pri kateri se v bakterijo vstavi gen (DNK), s katerim lahko tvori filgrastim.
The most common side effect with Ratiograstim (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). 
Najpogostejši neželeni učinek zdravila Ratiograstim (opažen pri več kot 1 bolniku od 10) je mišičnoskeletna bolečina (bolečina v mišicah in kosteh).
For more information about treatment with Ratiograstim, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ratiograstim preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
To study the safety of Ratiograstim, two further studies were carried out in patients with lung cancer and with non-Hodgkin's lymphoma. 
Za proučitev varnosti zdravila Ratiograstim sta bili izvedeni še dve študiji pri bolnikih s pljučnim rakom in z neHodgkinovim limfomom.
The active substance in Ratiograstim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G CSF). 
Zdravilna učinkovina v zdravilu Ratiograstim, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije stimulirajoči faktor (granulocyte colony stimulating factor - G CSF).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ratiograstim. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
A risk management plan has been developed to ensure that Ratiograstim is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Ratiograstim je bil pripravljen načrt obvladovanja tveganj.
Ratiograstim is used to stimulate the production of white blood cells in the following situations: 
Zdravilo Ratiograstim se uporablja za spodbujanje tvorbe belih krvničk v naslednjih primerih:
Ratiograstim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately. 
Zdravilo Ratiograstim se običajno daje v specializiranem zdravstvenem centru, vendar pa si ga lahko bolniki, ki ga prejemajo s podkožno injekcijo, dajejo tudi sami, pod pogojem, da so bili ustrezno usposobljeni.
Ratiograstim can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow. 
Zdravilo Ratiograstim se lahko uporablja tudi pri bolnikih, ki bi naj darovali matične celice za presaditev, za sproščanje teh celic iz kostnega mozga.
The Committee recommended that Ratiograstim be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Ratiograstim izda dovoljenje za promet.
Other side effects may be seen in more than 1 patient in 10, depending on the condition that Ratiograstim is being used for. 
Pri več kot 1 bolniku od 10 se lahko pojavijo tudi drugi neželeni učinki, odvisno od zdravstvenega stanja, zaradi katerega se zdravilo Ratiograstim uporablja.
Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk. 
Zato je CHMP menil, da so njegove koristi, kot pri zdravilu Neupogen, večje od z njim povezanih tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ratiograstim, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Ratiograstim was compared with Neupogen and with placebo (a dummy treatment) in one main study involving 348 patients with breast cancer. 
Zdravilo Ratiograstim so primerjali z zdravilom Neupogen in placebom (zdravilom brez zdravilne učinkovine) v eni glavni študiji, ki je vključevala 348 bolnic z rakom dojke.
Treatment with Ratiograstim and Neupogen brought about similar reductions in duration of severe neutropenia. 
Zdravljenje z zdraviloma Ratiograstim in Neupogen je privedlo do podobnega skrajšanja trajanja hude nevtropenije.
It contains the active substance filgrastim. 
Vsebuje zdravilno učinkovino filgrastim.
The study looked at the duration of severe neutropenia during the patients' first cycle of cytotoxic chemotherapy. 
Študija je proučevala trajanje hude nevtropenije med prvim ciklom citotoksične kemoterapije, ki ga je prejel bolnik.
What benefit has Ratiograstim shown during the studies? 
Kakšne koristi je zdravilo Ratiograstim izkazalo med študijami?
Ratiograstim is given by injection under the skin or infusion into a vein. 
Zdravilo Ratiograstim se daje z injekcijo pod kožo ali infuzijo v veno.
• to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing); 
• za zmanjšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in ob pojavu febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki jih zdravijo s kemoterapijo (zdravljenje raka), ki je citotoksična (ubija celice);